RxDoctor Payments Data

Stephen Wilkinson, MD

Cardiovascular Disease · Provo, UTNPI 1902149909

Payments from drug & device makers

What this record shows

This record is dominated by grants: $7,400 of the $8,326 with a category attached, or 88.9%. Medtronic accounts for 89.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $7,746 and has fallen 99.5% since, to $42 in 2025.

$8,326in general payments, 2019–2025

Across 30 payments — averaging $277.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Abbott$211
  • Cardiovascular Systems Inc.$124
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$111
  • Boston Scientific$79
  • Inari Medical, Inc.$71
  • plus $263 from 10 others

What the payments were for

  • Grants$7,40089%
  • Food & beverage$92611%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,326 in reported general payments places this provider in the 75th percentile of 131 cardiovascular disease providers in Utah.

See all cardiovascular disease providers in Utah

Medicare billing

Part B allowed, 2024
$96,286
Medicare patients
661
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban58$64,653
XareltoRivaroxaban23$26,943
JardianceEmpagliflozin23$24,458
Repatha SureclickEvolocumab20$14,406
Atorvastatin Calcium76$1,188
Carvedilol69$997
ClopidogrelClopidogrel Bisulfate73$943
Rosuvastatin Calcium89$937
Metoprolol Succinate76$785
Prasugrel Hcl14$764
Lisinopril40$641
Pravastatin Sodium22$550
Ezetimibe30$543
Losartan Potassium41$490
Spironolactone39$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$30$26,94323 claims
Boehringer IngelheimJardiance$23$24,45823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 131 cardiovascular disease providers in Utah.

Other cardiovascular disease in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →